MA33979B1 - Piperazines en tant qu'agents antipaludiques - Google Patents

Piperazines en tant qu'agents antipaludiques

Info

Publication number
MA33979B1
MA33979B1 MA35112A MA35112A MA33979B1 MA 33979 B1 MA33979 B1 MA 33979B1 MA 35112 A MA35112 A MA 35112A MA 35112 A MA35112 A MA 35112A MA 33979 B1 MA33979 B1 MA 33979B1
Authority
MA
Morocco
Prior art keywords
piperazine
antimalarial agents
formula
pharmaceutical compositions
relates
Prior art date
Application number
MA35112A
Other languages
Arabic (ar)
English (en)
Inventor
Hamed Aissaoui
Christoph Boss
Olivier Corminboeuf
Bibia Heidmann
Romain Siegrist
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA33979B1 publication Critical patent/MA33979B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de pipérazine de formule i ainsi que leur emploi en tant que principes actifs dans l'élaboration de compositions pharmaceutiques. La présente invention concerne également des aspects apparentés, y compris les compositions pharmaceutiques contenant un ou plusieurs de ces composés et leur emploi en tant que médicaments dans le traitement prophylactique ou thérapeutique d'infections à protozoaires, par exemple, spécialement, le paludisme. Formule (i).
MA35112A 2010-01-05 2011-01-04 Piperazines en tant qu'agents antipaludiques MA33979B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010050022 2010-01-05
IB2010052045 2010-05-10
PCT/IB2011/050009 WO2011083413A1 (fr) 2010-01-05 2011-01-04 Pipérazines en tant qu'agents antipaludiques

Publications (1)

Publication Number Publication Date
MA33979B1 true MA33979B1 (fr) 2013-02-01

Family

ID=43706300

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35112A MA33979B1 (fr) 2010-01-05 2011-01-04 Piperazines en tant qu'agents antipaludiques

Country Status (27)

Country Link
EP (1) EP2521715B1 (fr)
JP (1) JP5165166B1 (fr)
KR (1) KR101455484B1 (fr)
CN (1) CN102666488B (fr)
AR (1) AR079831A1 (fr)
AU (1) AU2011204436B2 (fr)
BR (1) BR112012016549A8 (fr)
CA (1) CA2783882C (fr)
CL (1) CL2012001641A1 (fr)
CY (1) CY1115600T1 (fr)
DK (1) DK2521715T3 (fr)
ES (1) ES2523739T3 (fr)
HR (1) HRP20140890T1 (fr)
IL (1) IL220698A (fr)
MA (1) MA33979B1 (fr)
MX (1) MX2012007172A (fr)
MY (1) MY160904A (fr)
NZ (1) NZ601607A (fr)
PH (1) PH12012501261A1 (fr)
PL (1) PL2521715T3 (fr)
PT (1) PT2521715E (fr)
RU (1) RU2555706C2 (fr)
SG (1) SG181462A1 (fr)
SI (1) SI2521715T1 (fr)
TW (1) TWI402267B (fr)
WO (1) WO2011083413A1 (fr)
ZA (1) ZA201205879B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018069A1 (fr) 2011-08-04 2013-02-07 Actelion Pharmaceuticals Ltd Combinaison d'agents antipaludéens
WO2014072903A1 (fr) * 2012-11-06 2014-05-15 Actelion Pharmaceuticals Ltd Nouveaux dérivés d'aminométhylphénol en tant qu'agents antipaludiques
MX2015012575A (es) 2013-03-15 2016-01-12 Actelion Pharmaceuticals Ltd Novedosos derivados de acrilamida como agentes contra la malaria.
WO2021149692A1 (fr) * 2020-01-21 2021-07-29 Eisai R&D Management Co., Ltd. Nouvel agent antipaludique contenant un composé hétérocyclique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
DE10008522A1 (de) * 2000-02-24 2001-09-06 Hassan Jomaa Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen
EP1268455A2 (fr) * 2000-03-31 2003-01-02 Pfizer Products Inc. Derives de piperazine
WO2007046075A1 (fr) * 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Derives de piperazine utilises comme agents antimalaria
CN101544630B (zh) * 2009-05-13 2013-03-13 中国科学院广州生物医药与健康研究院 羟基化茚地那韦的制备方法

Also Published As

Publication number Publication date
MX2012007172A (es) 2012-07-03
MY160904A (en) 2017-03-31
ES2523739T3 (es) 2014-12-01
BR112012016549A2 (pt) 2016-04-19
TW201139416A (en) 2011-11-16
PL2521715T3 (pl) 2014-11-28
JP2013516453A (ja) 2013-05-13
SG181462A1 (en) 2012-07-30
PT2521715E (pt) 2014-09-02
JP5165166B1 (ja) 2013-03-21
HRP20140890T1 (hr) 2014-11-07
AU2011204436B2 (en) 2016-05-19
BR112012016549A8 (pt) 2017-12-26
HK1178529A1 (en) 2013-09-13
NZ601607A (en) 2014-06-27
AU2011204436A1 (en) 2012-08-23
PH12012501261A1 (en) 2013-02-04
SI2521715T1 (sl) 2014-10-30
DK2521715T3 (da) 2014-08-11
TWI402267B (zh) 2013-07-21
WO2011083413A1 (fr) 2011-07-14
AR079831A1 (es) 2012-02-22
RU2012133265A (ru) 2014-02-20
KR101455484B1 (ko) 2014-10-27
CA2783882A1 (fr) 2011-07-14
ZA201205879B (en) 2015-04-29
KR20120111740A (ko) 2012-10-10
CA2783882C (fr) 2017-11-28
EP2521715A1 (fr) 2012-11-14
CY1115600T1 (el) 2017-01-04
RU2555706C2 (ru) 2015-07-10
IL220698A (en) 2015-09-24
EP2521715B1 (fr) 2014-06-25
CL2012001641A1 (es) 2012-12-07
CN102666488B (zh) 2015-04-22
CN102666488A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA38138A1 (fr) Dérivés inédits de quinolone
MA44674A (fr) Inhibiteurs de bromodomaine
MA30406B1 (fr) Nouveaux composes
MA35576B1 (fr) Nouveaux composés
MA33274B1 (fr) Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34474B1 (fr) Agonistes de gpr40
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA38556A1 (fr) Inhibiteurs de bace1
MA34308B1 (fr) Triazolopyridines substituées
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
BR112014003981A2 (pt) compostos de pirimido-piridazinona e seu uso
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse